Kenvue Inc. (NYSE:KVUE) Shares Sold by Procyon Advisors LLC

Procyon Advisors LLC lowered its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 78.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 13,772 shares of the company's stock after selling 50,865 shares during the period. Procyon Advisors LLC's holdings in Kenvue were worth $294,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in KVUE. Riverview Trust Co acquired a new position in shares of Kenvue in the third quarter valued at approximately $30,000. Fortitude Family Office LLC increased its stake in Kenvue by 106.6% in the 4th quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after buying an additional 777 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Kenvue in the 3rd quarter worth $35,000. Versant Capital Management Inc boosted its holdings in shares of Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock valued at $41,000 after acquiring an additional 1,441 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators increased its stake in shares of Kenvue by 49.7% during the third quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock worth $45,000 after acquiring an additional 651 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Jefferies Financial Group initiated coverage on Kenvue in a report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 price objective on the stock. Bank of America upped their price objective on Kenvue from $24.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, October 22nd. Piper Sandler raised Kenvue from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $26.00 in a report on Monday, January 6th. Barclays lowered their price target on shares of Kenvue from $23.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Friday. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a "buy" rating to a "hold" rating and decreased their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $23.08.

Kenvue Trading Down 0.4 %

Shares of NYSE KVUE traded down $0.09 during midday trading on Monday, reaching $21.11. 11,266,973 shares of the stock were exchanged, compared to its average volume of 8,612,558. The stock has a 50 day moving average price of $22.36 and a 200-day moving average price of $21.73. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $40.46 billion, a P/E ratio of 38.37, a P/E/G ratio of 1.99 and a beta of 1.46. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46.

Kenvue (NYSE:KVUE - Get Free Report) last issued its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion during the quarter, compared to the consensus estimate of $3.92 billion. During the same period in the previous year, the firm posted $0.31 EPS. Kenvue's revenue was down .4% on a year-over-year basis. Equities research analysts expect that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.89%. Kenvue's dividend payout ratio is presently 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.